Tevogen Bio Holdings Inc. (TVGN) NASDAQ
4.85
+0.085(+1.79%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
Tevogen Bio Holdings Inc.
Address
15 Independence Blvd
Warren, NJ 07059
United States of America (the)
Phone
877 838 6436
Website
Sector
Healthcare
Industry
Biotechnology
Employees
18
First IPO Date
January 05, 2022
Key Executives
| Name | Title | Pay | Year Born |
| Ryan H. Saadi | Co-Founder, Chief Executive Officer & Chairperson | 501,000 | 1965 |
| Kirti Desai | Chief Financial Officer | 300,000 | 1957 |
| Neal Flomenberg | Chief Scientific Officer and Global R&D Lead | 350,000 | 1954 |
| Mittul Mehta | Chief Information Officer & Head of Tevogen.ai | 0 | N/A |
| Tapan V. Shah | Head of Investor Relations & Corporate Development | 0 | N/A |
| David E. Banko | Global Head of Government Affairs & Patient Access | 0 | N/A |
| Sadiq Khan | Chief Commercial Officer & Interim Head of Tevogen Generics | 0 | 1962 |
| Stephen Chen | Chief Technical Officer | 0 | N/A |
Description
Tevogen Bio Holdings Inc. operates as a clinical-stage biotechnology company that develops off-the-shelf precision T cell therapeutics in virology, oncology, and neurology. Its lead investigational precision T cell product, TVGN 489, is designed to address the unmet need of acute-risk COVID-19 patients, as well as a subset of patients suffering from long COVID. The company is based in Warren, New Jersey.
